Kyowa Kirin Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Orc Manufacturing Co., Ltd.

Kyoto University

Hokkaido University

The University of Toyama

Shinya Ogawa

Kazuki Okada

Yuji Yamazaki

Naoya Kameyama

Munetoshi Ando

Hiroyuki Ariyama

Takenao Yamada

Tetsuya Kitayama

David Foster Mills

Yoshio Yazaki

Tsuyoshi Yamada

Andrew John McKnight

Rachel Soloff Nugent

Yoshiharu Sakai

Ayato Takada

Kaname Kimura

Makoto Taketo

Taira Maekawa

Nobuo Adachi

Kenji Kawada

Masayuki Kai

Giuseppe Destito

Sarah Sunrise Bubeck

Aruna Bitra

Dirk Michael Zajonc

Shigeru Iida

Hideyo Hirai

Reiko Yoshida

Yuko Ube

John Lorca Laudenslager

Ikuko Fujino

Junki Maruyama

Akiko Hariguchi

Wakako Furuyama

Masashi Ikutani

Kiyoshi Takatsu

Hiroko Miyamoto

Hiromi Ehara

Aihua Song

An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.

FN14 antibodies and uses thereof

An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.

Methods for treating hypertension using an anti-BMP10 monoclonal antibody or fragment thereof

A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

Anti-human CCR1 monoclonal antibody

Anti-BMP10 monoclonal antibody or fragment thereof

There has been a need for a neutralizing monoclonal antibody which is useful for antibody therapy effective against ebolavirus. The present invention provides a monoclonal antibody or an antigen-binding fragment thereof, which recognizes an internal fusion loop of ebolavirus GP and is capable of neutralizing the biological activity of ebolavirus.

Monoclonal antibody neutralizing infectivity of all ebola viruses

The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.

Anti human Gas6 monoclonal antibody

The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to 'IL-5R')-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.

Method for treating pulmonary hypertension with interleukin-5 receptor antibody

There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.

Antibody which specifically binds to human CRTH2

An exposure apparatus comprising lighting means such as ultra-violet lamp and reflecting mirror placed in an exposure room and also tray arranged to move in and out from the exposure room, wherein cooling means is provided. The cooling means blows cold air onto the surface of the tray. A cooling room is formed next to the exposure room. The cooling means is composed of air radiator and air fan. Refrigerant such as cold water passes through the air radiator and the air fan blows air in the cooling room onto the surface of the tray through the radiator. Exhaust fan arranged to send air in the exposure room into the cooling room is also provided between the exposure room and the cooling room.

Exposure apparatus

At least one strip of dry film assembly is supplied continuously to a plurality of mutually spaced apart boards which are also being fed continuously. The film assembly consists of a photosensitive layer sandwiched between a protective film and a base. The base is removed from the assembly when the assembly is supplied to the boards, so that each of the boards may be bonded to the photosensitive layer. The boards and the film assembly are fed intermittently, and the photosensitive layer is exposed to light to print a predetermined pattern on each board. The protective film is removed from the film assembly, and each printed board is subjected to developing treatment.

Method of manufacturing printed boards

Growing community of inventors

Tokyo, Japan

Shinya Ogawa